JP6995067B6 - ［１，２，４］トリアゾロ［１，５－ａ］ピリジニル置換インドール化合物 - Google Patents

［１，２，４］トリアゾロ［１，５－ａ］ピリジニル置換インドール化合物 Download PDF

Info

Publication number
JP6995067B6
JP6995067B6 JP2018568837A JP2018568837A JP6995067B6 JP 6995067 B6 JP6995067 B6 JP 6995067B6 JP 2018568837 A JP2018568837 A JP 2018568837A JP 2018568837 A JP2018568837 A JP 2018568837A JP 6995067 B6 JP6995067 B6 JP 6995067B6
Authority
JP
Japan
Prior art keywords
alkyl
triazolo
isopropyl
indol
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018568837A
Other languages
English (en)
Japanese (ja)
Other versions
JP6995067B2 (ja
JP2019523241A5 (enExample
JP2019523241A (ja
Inventor
アラリック・ジェイ・ディックマン
ダームパル・エス・ドッド
タシル・シャムスル・ハーク
ルイス・ジェイ・ロンバルド
ジョン・イー・マコー
クリストファー・ピー・マッサリ
ラクスマン・パスヌーリ
スリーカンタ・ラトナ・クマール
トレバー・シー・シャーウッド
ショシャナ・エル・ポージー
ラメシュ・クマール・シストラ
スブラマヤ・ヘッジ
アヌパマ・ラマチャンドラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019523241A publication Critical patent/JP2019523241A/ja
Publication of JP2019523241A5 publication Critical patent/JP2019523241A5/ja
Publication of JP6995067B2 publication Critical patent/JP6995067B2/ja
Application granted granted Critical
Publication of JP6995067B6 publication Critical patent/JP6995067B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2018568837A 2016-06-29 2017-06-28 ［１，２，４］トリアゾロ［１，５－ａ］ピリジニル置換インドール化合物 Active JP6995067B6 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201611022328 2016-06-29
IN201611022328 2016-06-29
US15/635,055 US10071079B2 (en) 2016-06-29 2017-06-27 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
US15/635,055 2017-06-27
PCT/US2017/039633 WO2018005586A1 (en) 2016-06-29 2017-06-28 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Publications (4)

Publication Number Publication Date
JP2019523241A JP2019523241A (ja) 2019-08-22
JP2019523241A5 JP2019523241A5 (enExample) 2020-08-06
JP6995067B2 JP6995067B2 (ja) 2022-01-14
JP6995067B6 true JP6995067B6 (ja) 2023-12-14

Family

ID=60805851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568837A Active JP6995067B6 (ja) 2016-06-29 2017-06-28 ［１，２，４］トリアゾロ［１，５－ａ］ピリジニル置換インドール化合物

Country Status (30)

Country Link
US (8) US10071079B2 (enExample)
EP (1) EP3478682B1 (enExample)
JP (1) JP6995067B6 (enExample)
KR (1) KR102473482B1 (enExample)
CN (1) CN109641895B (enExample)
AR (1) AR108905A1 (enExample)
AU (1) AU2017287902B2 (enExample)
CL (1) CL2018003821A1 (enExample)
CO (1) CO2019000686A2 (enExample)
CY (1) CY1124514T1 (enExample)
DK (1) DK3478682T3 (enExample)
EA (1) EA037530B1 (enExample)
ES (1) ES2886964T3 (enExample)
HR (1) HRP20211261T8 (enExample)
HU (1) HUE056091T2 (enExample)
IL (1) IL263961B (enExample)
LT (1) LT3478682T (enExample)
MX (1) MX376212B (enExample)
MY (1) MY196474A (enExample)
PE (1) PE20190324A1 (enExample)
PL (1) PL3478682T3 (enExample)
PT (1) PT3478682T (enExample)
RS (1) RS62292B1 (enExample)
SG (1) SG11201811590RA (enExample)
SI (1) SI3478682T1 (enExample)
SM (1) SMT202100513T1 (enExample)
TW (1) TWI636053B (enExample)
UY (1) UY37310A (enExample)
WO (1) WO2018005586A1 (enExample)
ZA (1) ZA201900571B (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX391344B (es) 2016-07-30 2025-03-21 Bristol Myers Squibb Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
FI3526323T3 (fi) 2016-10-14 2023-06-06 Prec Biosciences Inc Hepatiitti B -viruksen genomissa oleville tunnistussekvensseille spesifisiä muokattuja meganukleaaseja
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
ES2921020T3 (es) * 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
WO2019099336A1 (en) * 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
AU2018386201A1 (en) 2017-12-15 2020-07-30 Bristol-Myers Squibb Company Substituted indole ether compounds
US11878975B2 (en) * 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
CN111511730B (zh) 2017-12-19 2023-07-25 百时美施贵宝公司 可用作tlr抑制剂的被酰胺取代的吲哚化合物
SG11202005704RA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co 6-azaindole compounds
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
CA3085937A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
WO2019233941A1 (en) 2018-06-05 2019-12-12 F. Hoffmann-La Roche Ag Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease
US11713327B2 (en) 2018-06-12 2023-08-01 Hoffmann-La Roche Inc. Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
US20210269451A1 (en) * 2018-06-13 2021-09-02 Hoffmann-La Roche Inc. Pyridinyl heterocyclyl compounds for the treatment of autoimmune disease
JP7366994B2 (ja) 2018-07-23 2023-10-23 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患治療用の新規ピペラジン化合物
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
JP7233809B2 (ja) 2018-09-04 2023-03-07 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のためのベンゾチアゾール化合物
US12252484B2 (en) 2018-09-06 2025-03-18 Hoffmann-La Roche Inc. Pyrazolopyridine compounds for the treatment of autoimmune disease
WO2020048595A1 (en) 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Novel cyclic amidine compounds for the treatment of autoimmune disease
WO2020086503A1 (en) * 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
US11998537B2 (en) 2018-10-24 2024-06-04 Bristol-Myers Squibb Company Substituted indole dimer compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
PE20211655A1 (es) 2018-10-31 2021-08-24 Gilead Sciences Inc Compuestos de 6-azabencimidazol sustituidos como inhibidores de hpk1
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
CN114072403A (zh) * 2019-05-07 2022-02-18 百时美施贵宝公司 前药化合物
KR102904576B1 (ko) * 2019-05-09 2025-12-24 브리스톨-마이어스 스큅 컴퍼니 치환된 벤즈이미다졸론 화합물
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
CN110146631B (zh) * 2019-06-25 2021-11-12 山西康宝生物制品股份有限公司 一种药用材料中聚乙二醇单甲醚残留量的检测方法
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
EP4458975A3 (en) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021067326A1 (en) 2019-10-01 2021-04-08 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds
ES2965164T3 (es) 2019-10-04 2024-04-11 Bristol Myers Squibb Co Compuestos de carbazol sustituidos
EP4051387B1 (en) 2019-10-31 2025-02-19 F. Hoffmann-La Roche AG Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
US12486273B2 (en) 2019-11-19 2025-12-02 Hoffmann-La Roche Inc. Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
CN114728988B (zh) 2019-11-20 2024-12-10 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的螺(异苯并呋喃氮杂环丁烷)化合物
ES3022990T3 (en) 2019-12-06 2025-05-29 Prec Biosciences Inc Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
CA3181964A1 (en) * 2020-06-11 2021-12-16 Gary L. Schieven Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus
EP4168049A1 (en) 2020-06-22 2023-04-26 Bristol-Myers Squibb Company Treating rheumatoid arthritis
TW202214632A (zh) * 2020-07-27 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用
AU2021328577A1 (en) 2020-08-19 2023-03-23 Bristol-Myers Squibb Company 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis
US12486267B2 (en) 2020-08-19 2025-12-02 Bristol-Myers Squibb Company Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis
KR20230053645A (ko) 2020-08-19 2023-04-21 브리스톨-마이어스 스큅 컴퍼니 섬유증의 치료를 위한 tlr9 억제제로서의 1h-벤조[d]이미다졸 유도체
CN116490506B (zh) 2020-11-26 2024-12-13 江苏恒瑞医药股份有限公司 稠合三环化合物、其制备方法及其在医药上的应用
CN116783202A (zh) * 2021-02-09 2023-09-19 吉利德科学公司 噻吩并吡咯化合物
TWI861488B (zh) 2021-04-16 2024-11-11 美商基利科學股份有限公司 噻吩并吡咯化合物
AU2022274607A1 (en) 2021-05-13 2023-11-16 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
CN113416188B (zh) * 2021-05-31 2022-12-13 河南偶联生物科技有限公司 一种[1,2,4]三唑并[1,5-a]吡啶化合物的合成方法
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US12070455B2 (en) 2021-09-10 2024-08-27 Gilead Sciences, Inc. Thienopyrrole compounds
EP4554932A1 (en) 2022-07-13 2025-05-21 Bristol-Myers Squibb Company Processes for preparing 5-bromo-3,4-dimethylpyridin-2-amine and 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine
IL327216A (en) 2023-10-02 2026-05-01 Bristol Myers Squibb Co A method for treating lupus
AU2024380732A1 (en) 2023-11-13 2026-04-16 Bristol-Myers Squibb Company 2-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl- 1h-indol-5-yl)piperidin-1-yl)acetamide and crystalline forms thereof
TW202527943A (zh) 2023-11-13 2025-07-16 美商必治妥美雅史谷比公司 2-(4-(2-(7,8-二甲基-[1,2,4]三唑[1,5-a]吡啶-6-基)-3-異丙基-1h-吲哚-5-基)哌啶-1-基)乙醯胺鹽及其結晶形式
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2026015723A1 (en) * 2024-07-12 2026-01-15 University Of Maryland, Baltimore Methods of treating ischemia/reperfusion injury

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
JP2012517471A (ja) 2009-02-11 2012-08-02 スノビオン プハルマセウトイカルス インコーポレイテッド ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
JP2012529529A (ja) 2009-06-10 2012-11-22 スノビオン プハルマセウトイカルス インコーポレイテッド ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
JP2014520846A (ja) 2011-07-13 2014-08-25 エスケー ケミカルズ カンパニー リミテッド Ａｌｋ５及び／又はａｌｋ４の抑制剤としての２−ピリジル置換イミダゾール類

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200100323A (et) 1998-12-18 2002-08-15 Axys Pharmaceuticals, Inc. (Hetero)arüüli - bitsüklilise heteroarüüli derivaadid, nende valmistamine ja nende kasutamine proteaasiinhibiitoritena
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
JP2009532501A (ja) 2006-04-04 2009-09-10 ミリアド ジェネティクス， インコーポレイテッド 疾患および障害のための化合物
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
ATE495743T1 (de) 2006-12-01 2011-02-15 Galapagos Nv Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
EP2350032B1 (en) 2008-09-26 2016-05-25 Eisai R&D Management Co., Ltd. Benzoxazole compounds and methods of use
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
TR201809739T4 (tr) 2009-07-16 2018-07-23 Mallinckrodt Llc Toll benzeri reseptör 9 antagonistleri olarak (+)-morfinanlar ve bunların terapötik amaçlı kullanımları.
US9241991B2 (en) 2010-10-21 2016-01-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritus and related skin conditions
ES2620605T3 (es) 2011-01-12 2017-06-29 Ventirx Pharmaceuticals, Inc. Benzoazepinas sustituidas como moduladores de receptores tipo Toll
CA2824779C (en) 2011-01-12 2020-01-14 Array Biopharma, Inc. Substituted benzoazepines as toll-like receptor modulators
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
RU2606114C2 (ru) 2011-06-01 2017-01-10 Джейнус Байотерапьютикс, Инк. Новые модуляторы иммунной системы
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
EP2850067B1 (en) 2012-05-18 2017-08-16 Sumitomo Dainippon Pharma Co., Ltd. Carboxylic acid compounds
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
TWI624467B (zh) 2013-10-14 2018-05-21 衛材Ｒ＆Ｄ企管股份有限公司 選擇性經取代之喹啉化合物
CA2933466A1 (en) 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
WO2016029077A1 (en) 2014-08-22 2016-02-25 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
FI3478670T3 (fi) 2016-06-29 2023-05-04 Kezar Life Sciences Peptidi-epoksiketoni-immunoproteasomi-estäjän kiteiset suolat
SG11201811697SA (en) 2016-06-29 2019-01-30 Hanmi Pharmaceutical Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
US10071079B2 (en) * 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX391344B (es) 2016-07-30 2025-03-21 Bristol Myers Squibb Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
CN110997656B (zh) 2017-08-04 2023-04-14 百时美施贵宝公司 用作tlr7/8/9抑制剂的取代的吲哚化合物
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
AU2018386201A1 (en) 2017-12-15 2020-07-30 Bristol-Myers Squibb Company Substituted indole ether compounds
JP7289301B2 (ja) 2017-12-18 2023-06-09 ブリストル－マイヤーズ スクイブ カンパニー ４－アザインドール化合物
CN111511730B (zh) 2017-12-19 2023-07-25 百时美施贵宝公司 可用作tlr抑制剂的被酰胺取代的吲哚化合物
SG11202005704RA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co 6-azaindole compounds
US11878975B2 (en) 2017-12-19 2024-01-23 Bristol-Myers Squibb Company Substituted indole compounds useful as TLR inhibitors
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
CA3085937A1 (en) 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
US11998537B2 (en) 2018-10-24 2024-06-04 Bristol-Myers Squibb Company Substituted indole dimer compounds
WO2020086503A1 (en) 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
JP2012517471A (ja) 2009-02-11 2012-08-02 スノビオン プハルマセウトイカルス インコーポレイテッド ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
JP2012529529A (ja) 2009-06-10 2012-11-22 スノビオン プハルマセウトイカルス インコーポレイテッド ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
JP2014520846A (ja) 2011-07-13 2014-08-25 エスケー ケミカルズ カンパニー リミテッド Ａｌｋ５及び／又はａｌｋ４の抑制剤としての２−ピリジル置換イミダゾール類

Also Published As

Publication number Publication date
HUE056091T2 (hu) 2022-01-28
KR102473482B1 (ko) 2022-12-01
JP6995067B2 (ja) 2022-01-14
IL263961A (en) 2019-01-31
SG11201811590RA (en) 2019-01-30
US10478424B2 (en) 2019-11-19
IL263961B (en) 2021-01-31
PT3478682T (pt) 2021-09-15
US20200038374A1 (en) 2020-02-06
UY37310A (es) 2018-01-02
AU2017287902A1 (en) 2019-02-14
DK3478682T3 (da) 2021-09-13
US10071079B2 (en) 2018-09-11
US20230255941A1 (en) 2023-08-17
HRP20211261T1 (hr) 2021-11-26
MY196474A (en) 2023-04-13
BR112018077119A2 (pt) 2019-04-02
US11672780B2 (en) 2023-06-13
CL2018003821A1 (es) 2019-04-22
CO2019000686A2 (es) 2019-02-19
KR20190022735A (ko) 2019-03-06
NZ750180A (en) 2024-07-26
US20180000790A1 (en) 2018-01-04
CN109641895B (zh) 2021-09-03
EP3478682A1 (en) 2019-05-08
TWI636053B (zh) 2018-09-21
WO2018005586A1 (en) 2018-01-04
SMT202100513T1 (it) 2021-11-12
SI3478682T1 (sl) 2021-10-29
CA3029620A1 (en) 2018-01-04
EA037530B1 (ru) 2021-04-08
US20180325874A1 (en) 2018-11-15
PL3478682T3 (pl) 2021-12-13
US10912766B2 (en) 2021-02-09
CN109641895A (zh) 2019-04-16
US20210085651A1 (en) 2021-03-25
USRE49931E1 (en) 2024-04-23
EA201990048A1 (ru) 2019-05-31
LT3478682T (lt) 2021-09-27
PE20190324A1 (es) 2019-03-05
CY1124514T1 (el) 2022-07-22
ZA201900571B (en) 2020-10-28
ES2886964T3 (es) 2021-12-21
JP2019523241A (ja) 2019-08-22
RS62292B1 (sr) 2021-09-30
HRP20211261T8 (hr) 2022-01-21
AU2017287902B2 (en) 2021-09-16
USRE49880E1 (en) 2024-03-26
USRE49893E1 (en) 2024-04-02
AR108905A1 (es) 2018-10-10
EP3478682B1 (en) 2021-07-21
MX2018015422A (es) 2019-04-22
MX376212B (es) 2025-03-07
TW201805285A (zh) 2018-02-16

Similar Documents

Publication Publication Date Title
USRE49931E1 (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
AU2017307208B2 (en) Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
KR102742181B1 (ko) 6-아자인돌 화합물
KR102519535B1 (ko) 피리딜 치환된 인돌 화합물
KR102688509B1 (ko) [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
KR102781141B1 (ko) 치환된 인돌 에테르 화합물
JP2021507918A (ja) Ｔｌｒ阻害剤として有効なアミノインドール化合物
JP2021506889A (ja) Ｔｌｒ阻害剤として有効な置換されたインドール化合物
CA3029620C (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
HK40005511A (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
HK40005511B (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
BR112018077119B1 (pt) COMPOSTOS INDÓIS SUBSTITUÍDOS COM [1,2,4]TRIAZOL[1,5-a]PIRIDINILA, USO DOS MESMOS, E COMPOSIÇÃO FARMACÊUTICA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200626

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211214

R150 Certificate of patent or registration of utility model

Ref document number: 6995067

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250